The long-term treatment of steroid osteoporosis with fluoride. 1990

T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
St. Joseph's Health Centre, Toronto General Hospital, Ontario, Canada.

Twenty-two patients with steroid-induced osteoporosis were studied retrospectively to assess the effects on bone mass of fluoride therapy over 4 years. Thirteen of 19 patients with miscellaneous disorders and 2 with Cushing's syndrome received 1 g calcium/day, 50,000 IU vitamin D (D) weekly, and 40-60 mg/day sodium fluoride (F). Six patients with miscellaneous disorders and one with Cushing's syndrome received only Ca and vitamin D. The mean (+/- SD) cumulative dose of prednisone for fluoride-treated patients at the beginning of the study was 42 +/- 25 g, and for those patients treated with only Ca and vitamin D, 45 +/- 47 g, and during the study the cumulative dose was comparable in both groups. The bone mineral mass of the central skeleton was measured by neutron activation analysis and the results expressed as the calcium bone index (CaBI) which normalizes the results to that of young adults of the same body size (normal range 0.75-1.2). In the 13 patients with miscellaneous disorders treated with fluoride, the mean +/- SD CaBI rose from 0.65 +/- .03 to 0.75 +/- .03 after 3 years p less than 0.001) and to 0.81 +/- .11 at 4 years. Patients without fluoride had an initial mean CaBI of 0.70 +/- .08 and it was not significantly changed over 3 years, 0.68 +/- .09 and 4 years, 0.71 +/- .09. The rise in CaBI in fluoride-treated patients with steroid-induced osteoporosis including Cushing's syndrome was comparable to that of 61 patients with postmenopausal osteoporosis treated with fluoride.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012969 Sodium Fluoride A source of inorganic fluoride which is used topically to prevent dental caries. Fluoristat,Ossin,Zymafluor,Fluoride, Sodium,Fluorides, Sodium,Fluoristats,Ossins,Sodium Fluorides,Zymafluors
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
January 1986, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
January 1986, Bone,
T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
February 1978, Deutsche medizinische Wochenschrift (1946),
T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
May 1974, Helvetica medica acta,
T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
August 1988, Schweizerische medizinische Wochenschrift,
T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
December 1982, Journal of the Oslo city hospitals,
T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
May 1993, Medicina clinica,
T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
January 1972, Seminars in drug treatment,
T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
September 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
T A Bayley, and C Muller, and J Harrison, and J Basualdo, and W Sturtridge, and R Josse, and T M Murray, and K P Pritzker, and R Vieth, and S Goodwin
February 1965, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!